ReNeuron Raises $50M For Stem Cell Trials In Stroke, Limb Ischemia And Sight Loss
This article was originally published in The Pink Sheet Daily
New and existing investors back early clinical studies by leading U.K. stem cell company ReNeuron, including potential therapies for stroke, limb ischemia, and retinitis pigmentosa, as well as other sight destroying conditions like age-related macular degeneration.
You may also be interested in...
The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.